NCT05761223 2025-08-17
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
1ST Biotherapeutics, Inc.
Phase 1/2 Recruiting
1ST Biotherapeutics, Inc.
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Anaveon AG
DualityBio Inc.